8-K: Owlet Announces Strong First Quarter 2025 Results, Revenue Up 43.1%

Owlet, Inc. reports a 43.1% increase in revenue for Q1 2025, alongside improved gross margins and progress towards adjusted EBITDA profitability.

Summary

• Owlet, Inc. reported its financial results for the first quarter ended March 31, 2025.
• Q1 revenue reached $21.1 million, a 43.1% increase compared to $14.8 million in Q1 2024, driven by higher sales of Dream Sock and Dream Duo products.
• Gross margin improved to 53.7%, up 930 basis points from 44.4% in Q1 2024, due to higher revenue, favorable product mix, decreasing return rates, and lower costs.
• Net income was $3.0 million, compared to $3.3 million in Q1 2024, including a $6.7 million gain on warrant mark-to-market.
• Adjusted EBITDA was $0.0 million, an improvement of $3.1 million compared to a loss of $3.1 million in Q1 2024.
• The company is updating its 2025 financial outlook, now expecting revenue in the range of $91 million to $95 million, representing 17% to 22% year-over-year growth.
• Gross margins are projected to be in the range of 46% to 50%, including the impact of new expected tariff costs.
• Owlet continues to strive for full-year 2025 adjusted EBITDA profitability.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue growth, improved gross margins, and progress towards profitability. Management's comments are optimistic, and the company is well-positioned for future growth. However, some risks and uncertainties remain, preventing a perfect score.

Positives

• Significant revenue growth of 43.1% year-over-year in Q1 2025.
• Substantial improvement in gross margin, increasing by 930 basis points.
• Breakeven adjusted EBITDA achieved in Q1 2025, demonstrating improved financial performance.
• Growth driven by strong sales of Dream Sock and Dream Duo products.
• Positive trends in decreasing overall return rates and lower product costs.
• New distribution partnership with Children's Hospital of The Kings Daughters.
• FDA and CE-cleared infant health monitors provide a competitive advantage.
• Owlet360 subscription service gaining traction with over 48,000 paying subscribers.

Negatives

• Net income decreased slightly to $3.0 million from $3.3 million in Q1 2024.
• Operating expenses increased due to higher compensation expense and legal charges.
• Operating loss was $2.7 million for the first quarter of 2025, compared to operating loss of $5.7 million for the first quarter of 2024.

Risks

• Regulatory risks associated with obtaining and maintaining approvals for Owlet's products.
• Competition in the market for infant monitoring products.
• The company's ability to manage growth and achieve profitability.
• Risks associated with debt agreements and the ability to generate sufficient cash flow.
• Potential impact of economic conditions, health epidemics, and trade restrictions on Owlet's business.
• The company's ability to protect its intellectual property and maintain relationships with key stakeholders.

Future Outlook

Owlet expects revenue in the range of $91 million to $95 million for the full year 2025, representing 17% to 22% growth year-over-year, and gross margins in the range of 46% to 50%. The company continues to strive for full-year 2025 adjusted EBITDA profitability.

Management Comments

• Kurt Workman, Owlet's Chief Executive Officer and Co-Founder, stated that Owlet had an exceptional start to the year with first quarter revenue, gross margin, and adjusted EBITDA all exceeding expectations.
• Workman highlighted the 43% year-over-year revenue growth and the fourth consecutive quarter of breakeven or better adjusted EBITDA.
• Workman mentioned the new distribution partnership with Children's Hospital of The Kings Daughters.
• Workman noted the significant momentum for the core Dream Sock and Dream Duo products.
• Workman discussed the three incremental growth drivers of international expansion, medical and healthcare channels, and the Owlet360 subscription service.
• Workman concluded that the company is well-positioned to continue driving durable growth in 2025 and beyond.

Industry Context

Owlet's focus on smart infant monitoring and FDA-cleared medical devices positions it well in the growing digital health and telehealth market. The company's expansion into medical channels and subscription services aligns with industry trends towards personalized and preventative healthcare solutions.

Comparison to Industry Standards

• Comparable companies in the consumer health and wearable technology space include Fitbit, Garmin, and Apple (with its health features).
• Owlet's 43.1% revenue growth in Q1 2025 is strong compared to the average growth rates of established players in the consumer electronics market.
• The gross margin improvement of 930 basis points indicates efficient cost management and a favorable product mix, which is a positive sign compared to industry benchmarks.
• Achieving breakeven adjusted EBITDA is a significant milestone, demonstrating progress towards sustainable profitability, which is a key metric for investors in the growth equity space.

Stakeholder Impact

• Shareholders will likely react positively to the strong financial results and optimistic outlook.
• Employees may benefit from increased job security and potential bonuses.
• Customers will continue to have access to innovative infant monitoring products.
• Suppliers and manufacturers will benefit from increased demand for Owlet's products.
• Creditors will be reassured by the company's improved financial performance.

Next Steps

• Owlet will host a conference call and webcast on May 8, 2025, to discuss the results and provide a business update.
• The company will continue to focus on driving revenue growth, improving gross margins, and achieving adjusted EBITDA profitability in 2025.
• Owlet will continue to expand its product offerings, distribution channels, and international presence.

Key Dates

Keywords

Owlet, infant monitoring, financial results, revenue, gross margin, adjusted EBITDA, Dream Sock, Dream Duo, healthcare, pediatric, subscription service